Flash Update Sent November 10, 2010
NCCN has published updates to the NCCN Guidelines™ and NCCN Drugs & Biologics Compendium (NCCN Compendium™) for Kidney Cancer. These NCCN Guidelines are currently available as Version 1.2011.
Significant updates include:
Flash Update Sent November 17, 2010
NCCN has published updates to the NCCN Guidelines for Ovarian Cancer. These NCCN Guidelines are currently available as Version 2.2011.
Based on recent clinical trial data, the panel revised the discussion regarding bevacizumab by adding information about the ICON7 trial and the following statement: “Until there are more mature results from GOG 0218 and ICON7, the NCCN Guidelines Panel for Ovarian Cancer does not recommend the routine addition of bevacizumab to upfront therapy with carboplatin/paclitaxel or as maintenance therapy at this time. The NCCN panel encourages participation in ongoing clinical trials that are further investigating the role of anti-angiogenesis agents in the treatment of ovarian cancer, both in the upfront and recurrence settings.”
Flash Update Sent November 19, 2010
NCCN has published updates to the NCCN Guidelines for Colon and Rectal Cancers. These NCCN Guidelines are both currently available as Version 2.2011 (Colon) and Version 3.2011 (Rectal).
Based upon recent presentations, the previous footnote related to BRAF mutations was removed and the following footnotes were added to the metastatic section of the NCCN Guidelines for Colon and Rectal Cancers:
For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.